Listen to Story New drug Zaynich has shown 97% effectiveness against multi-drug resistant infections It is currently nearing completion of a multi-national Phase III study Zaynich is a combination of ...

Mumbai: Wockhardt has announced that Zaynich (Zidebactam/Cefepime, WCK 5222) demonstrated over 97 percent clinical efficacy in treating seriously ill patients with infections caused by ...

and E. coli. Treatment durations ranged from 7 to 21 days, and the study protocol was approved by the Drugs Controller General of India (DCGI). Zaynich, a combination of Zidebactam & Cefepime, is ...

"In a ground-breaking clinical study, Zaynich (Zidebactam/Cefepime, WCK 5222) demonstrated over 97 per cent clinical efficacy in treating seriously ill patients with infections caused by ...

Wockhardt Limited announced that its innovative antibiotic, Zaynich (Zidebactam/Cefepime), demonstrated over 97% clinical efficacy in treating serious infections ...

In a retrospective, observational analysis, the authors found that empirical V- piperacillin-tazobactam was associated with a higher mortality than V-cefepime. V-piperacillin-tazobactam’s ...

Purpose: The pharmacology, spectrum of activity, pharmacokinetics, clinical efficacy, adverse events, dosage and administration, drug interactions, and place in therapy of tigecycline are reviewed ...